Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Oncothyreon Inc. Stories

2011-05-06 12:53:00

SEATTLE, May 6 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that it will conduct a conference call to discuss its first quarter 2011 financial results and provide a review of its pipeline of products in development on Friday, May 6, 2011 at 4:30 p.m. Eastern time. To participate in the call by telephone, please dial (877) 280-7291 (United States) or (707) 287-9361 (International). In addition, the call will be webcast live and can be accessed on the...

2011-05-04 15:05:00

SEATTLE, May 4 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced that it has closed an underwritten public offering of 11,500,000 shares of its common stock at a price to the public of $4.00 per share for gross proceeds of $46.0 million. The shares include 1,500,000 shares of common stock sold pursuant to the over-allotment option granted by the Company to the underwriters, which option was exercised in full. The net proceeds from the sale of the shares, after...

2011-05-03 10:59:00

In TO951 sent today at 08:00 ET please note there is an error in the headline which should instead read "Oncothyreon to Present at JMP Securities Research Conference" and not "Oncothyreon to Present at JMP Securities Healthcare Conference". Corrected copy follows: Oncothyreon to Present at JMP Securities Research Conference SEATTLE, WA, May 3 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive...

2011-05-02 15:24:00

SEATTLE, WA, May 2 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that it will conduct a conference call to discuss its first quarter 2011 financial results and provide a review of its pipeline of products in development on Friday, May 6, 2011 at 1:30 p.m. Eastern time. To participate in the call by telephone, please dial (877) 280-7291 (United States) or (707) 287-9361 (International). In addition, the call will be webcast live and can be accessed on the...

2011-04-29 07:02:00

SEATTLE, April 29 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced that it has priced an underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $4.00 per share for gross proceeds of $40.0 million. The net proceeds from the sale of the shares, after deducting the underwriters' discounts and other estimated offering expenses payable by Oncothyreon, will be approximately $37.4 million. Oncothyreon has also granted the...

2011-04-28 15:01:00

SEATTLE, April 28 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced its intention to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering. Oncothyreon also expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering to cover over-allotments, if any. The proceeds of the offering will primarily be used to fund the...

2011-04-04 05:00:00

SEATTLE, WA, April 4 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced the presentation of preclinical data for ONT-10, a therapeutic vaccine directed at cancers expressing MUC1, and PX-866, its irreversible inhibitor of phosphatidylinositol 3-kinase (PI3K), at the American Association of Cancer Research meeting in Orlando, Florida. ONT-10 ONT-10 is a therapeutic vaccine targeting MUC1 which has been designed to stimulate both the humoral and cellular arms...

2011-03-29 07:00:00

SEATTLE, WA, March 29 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that the Company will be presenting at the following scientific & investor conferences during April: American Association of Cancer Research 102(nd) Annual Conference Preclinical data about ONT-10, Oncothyreon's proprietary, follow-on cancer vaccine, and PX-866, the Company's irreversible inhibitor of phosphatidylinositol 3-kinase (PI3K), will be highlighted in the following poster...

2011-03-10 06:00:00

COMPANY TO HOLD CONFERENCE CALL AT 8:00 EST TODAY SEATTLE, WA, March 10 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) (the "Company") today reported financial results for the year and quarter ending December 31, 2010.  Net loss for the year ended December 31, 2010 was $15.6 million, or $0.58 per basic and diluted share, compared with net loss of $17.2 million, or $0.76 per basic and diluted share for the year ended December 31, 2009.  The decrease in net loss...

2011-03-01 07:05:00

SEATTLE, March 1 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that the company will be presenting at the following industry and investor conferences during March:  -- 11th Annual Life Science Innovation Northwest Conference: Julie Eastland, Oncothyreon's Chief Financial Officer, will present at this life sciences conference in Seattle on Wednesday, March 2 at 1:45 p.m. Pacific Time. -- 22nd Annual...